Patent Application for Dispersible Pharmaceutical Formulations
Summary
The USPTO has published patent application US20260083690A1 concerning dispersible pharmaceutical formulations of a specific chemical compound. The application details the composition and potential uses of these formulations.
What changed
This document is a published patent application from the USPTO for a new pharmaceutical formulation. The application, identified as US20260083690A1, describes dispersible pharmaceutical compositions containing N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and optionally a pharmaceutically acceptable carrier.
As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on drug manufacturers. However, it represents a step in the intellectual property protection process for novel drug formulations, which could impact future market exclusivity and product development strategies for pharmaceutical companies.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2- FLUORO-4-IODO-PHENYLAMINO)-BENAZMIDE AND USES THEREOF
Application US20260083690A1 Kind: A1 Mar 26, 2026
Inventors
Kristin PATTERSON, Jiping LIU
Abstract
The present disclosure relates to dispersible pharmaceutical compositions comprising N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier.
CPC Classifications
A61K 31/167 A61K 9/0056 A61K 9/16 A61K 9/2013 A61K 9/2018 A61K 9/2054 A61K 9/2072
Filing Date
2025-06-11
Application No.
19234475
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.